Global Cell Therapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Cell Type;

Stem Cell (Bone Marrow, Blood, Umbilical Cord-Derived, and Adipose-Derived Stem Cell.

By Therapy;

Allogenic Therapies and Autologous Therapies.

By Therapeutic Area;

Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology, and Others.

By End User;

Hospitals & Clinics, and Academic & Research Institutes.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn925171978 Published Date: February, 2025 Updated Date: March, 2025

Introduction

Global Cell Therapy Market (USD Million), 2021 - 2031

In the year 2023, the Global Cell Therapy Market was valued at USD 9,377.63 million. The size of this market is expected to increase to USD 40,860.10 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 23.4%.

One of the defining features of cell therapy is its diverse applicability across multiple therapeutic areas, including oncology, neurology, cardiology, orthopedics, autoimmune disorders, and rare genetic diseases. From treating cancer through adoptive cell transfer therapies like chimeric antigen receptor (CAR) T-cell therapy to repairing damaged heart tissue with cardiac stem cell transplantation, cell-based interventions offer promising avenues for addressing unmet medical needs and improving patient outcomes.

The escalating prevalence of chronic diseases, aging populations, and the growing burden of degenerative conditions have underscored the urgent need for innovative therapeutic approaches capable of addressing complex disease mechanisms and achieving long-term clinical benefits. Cell therapy, with its potential to target disease at the cellular level and provide personalized treatment solutions, has emerged as a transformative paradigm in modern medicine.

The convergence of cutting-edge technologies such as gene editing, tissue engineering, and biomaterials with cell therapy has unlocked new possibilities for enhancing the safety, efficacy, and scalability of cell-based interventions. From engineering cells to express therapeutic genes to developing biomimetic scaffolds that mimic the natural microenvironment for cell growth and differentiation, these technological advancements are driving the next wave of innovation in regenerative medicine. Regulatory agencies worldwide have established clear guidelines for the development, manufacturing, and commercialization of cell-based products, ensuring patient safety while fostering innovation and market growth.

As the global cell therapy market continues to expand, key stakeholders including pharmaceutical companies, biotechnology firms, academic institutions, and healthcare providers are investing heavily in research and development efforts to advance the field. Collaborative initiatives, strategic partnerships, and investments in infrastructure and manufacturing capabilities are driving progress towards realizing the full potential of cell therapy as a cornerstone of 21st-century medicine.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Cell Type
    2. Market Snapshot, By Therapy
    3. Market Snapshot, By Therapeutic Area
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Global Cell Therapy Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Prevalence of Chronic Diseases
        2. Growing Investment and Funding
        3. Expanding Pipeline of Cell Therapies
      2. Restraints
        1. High Development Costs
        2. Ethical and Societal Issues
        3. Complex Manufacturing Processes
      3. Opportunities
        1. Expanding Applications
        2. Manufacturing Efficiency and Scalability
        3. Combination Therapies and Combinatorial Approaches
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Cell Therapy Market, By Cell Type, 2021 - 2031 (USD Million)
      1. Stem Cell
        1. Bone Marrow
        2. Blood
      2. Umbilical Cord
        1. Derived
      3. Adipos
        1. Derived Stem Cell
    2. Global Cell Therapy Market, By Therapy, 2021 - 2031 (USD Million)
      1. Allogenic Therapies
      2. Autologous Therapies
    3. Global Cell Therapy Market, By Therapeutic Area, 2021 - 2031 (USD Million)
      1. Oncology
      2. Cardiovascular Disease (CVD)
      3. Musculoskeletal Disorders
      4. Dermatology
      5. Others
    4. Global Cell Therapy Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis AG
      2. Gilead Sciences, Inc.
      3. Bristol-Myers Squibb Company
      4. Johnson & Johnson Services, Inc
      5. JCR Pharmaceuticals Co., Ltd.
      6. JW Therapeutics
      7. Atara Biotherapeutics
      8. Anterogen Co., Ltd.
      9. MEDIPOST
      10. S. BIOMEDICS
      11. Aurion Biotech
      12. Holostem Terapie Avanzate S.r.l
      13. Nkarta, Inc.
  7. Analyst Views
  8. Future Outlook of the Market